EPR-Technologies announces new approach to emergency care when CPR fails
EPR-Technologies is pursuing development of an unprecedented standard of emergency care when CPR fails
EPR-Technologies is pursuing development of an unprecedented standard of emergency care when CPR fails
Site has a capital investment program of ~$30 million spent or committed over the last three years to expand capabilities and improve operational efficiencies
Redbiotec has a right to royalties on Eurocine Vaccines´ net sales of an approved HSV-2 vaccine, should such sales arise.
Gilman will be responsible for all business development and portfolio strategy efforts globally.
Alopecia areata usually presents as a few small bald patches in the head
The proposed transaction involves the sale of the global biosimilars portfolio of Viatris to Biocon Biologics
The proposed combination involves corporate restructuring of JVCO, including through acquisition by Haleon via demerger
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Strides was granted a Competitive Generic Therapy (CGT) designation for its ANDA.
Tislelizumab is now approved in nine indications in China
Subscribe To Our Newsletter & Stay Updated